[mu]-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer
Structure-dependent [mu]-opioid receptor (MOR) activity is an important element in cancer opioid analgesic effectiveness. It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern. This is associated with decreased...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2015-06, Vol.36 (6), p.4655 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 4655 |
| container_title | Tumor biology |
| container_volume | 36 |
| creator | Cieliska, Anna Sienkiewicz-szapka, Edyta Kostyra, Elbieta Fiedorowicz, Ewa Snarska, Jadwiga Wroski, Konrad Tenderenda, Micha Jarmoowska, Beata Matysiewicz, Micha |
| description | Structure-dependent [mu]-opioid receptor (MOR) activity is an important element in cancer opioid analgesic effectiveness. It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern. This is associated with decreased binding ability in both exogenous and endogenous opioids, resulting in increased human pain resistance. The endogenous opioid system's function in body homeostasis maintenance is considered mainly regulatory, so its participation in breast tumor formation and progression is identified herein. We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies. Our results highlight a strong association between G allele presence at [mu]-opioid receptor A118G and increased breast cancer incidence (OR=3.3, 95 % CI 2.2-5.0, p |
| doi_str_mv | 10.1007/s13277-015-3113-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1702210747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3771765211</sourcerecordid><originalsourceid>FETCH-proquest_journals_17022107473</originalsourceid><addsrcrecordid>eNqNisFOAjEUABsDiSB8gLeXeMFD9b12tXA2Gi5kCeFmCFmWp5SwbW27Ifr17oEP4DSTzAhxT_hEiOY5kVbGSKQXqYm0_LsRAyqUlqin2OscCWWhpvpWDFM6YjfOZq8Dsfhs2o0sg_V2D5FrDtlH-GbHMCmXqwU9QvCn38bHcLCpAesgVNmyywnONh9gF7lKGerK1RxHov9VnRKPL7wTDx_v67e5DNH_tJzy9ujb6Lq0JYNKEZrC6Ouuf-26Q-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1702210747</pqid></control><display><type>article</type><title>[mu]-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer</title><source>SpringerLink Journals</source><creator>Cieliska, Anna ; Sienkiewicz-szapka, Edyta ; Kostyra, Elbieta ; Fiedorowicz, Ewa ; Snarska, Jadwiga ; Wroski, Konrad ; Tenderenda, Micha ; Jarmoowska, Beata ; Matysiewicz, Micha</creator><creatorcontrib>Cieliska, Anna ; Sienkiewicz-szapka, Edyta ; Kostyra, Elbieta ; Fiedorowicz, Ewa ; Snarska, Jadwiga ; Wroski, Konrad ; Tenderenda, Micha ; Jarmoowska, Beata ; Matysiewicz, Micha</creatorcontrib><description>Structure-dependent [mu]-opioid receptor (MOR) activity is an important element in cancer opioid analgesic effectiveness. It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern. This is associated with decreased binding ability in both exogenous and endogenous opioids, resulting in increased human pain resistance. The endogenous opioid system's function in body homeostasis maintenance is considered mainly regulatory, so its participation in breast tumor formation and progression is identified herein. We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies. Our results highlight a strong association between G allele presence at [mu]-opioid receptor A118G and increased breast cancer incidence (OR=3.3, 95 % CI 2.2-5.0, p<0.0001) and female gender (OR=2.0, 95 % CI 1.4-2.9, p=0.0004). Consequently, OPRM1 G allele presence at that site is a highly significant risk factor in breast cancer development.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-015-3113-z</identifier><language>eng</language><publisher>London: Springer Nature B.V</publisher><subject>Analgesics ; Breast cancer ; Homeostasis ; Pain management ; Polymorphism</subject><ispartof>Tumor biology, 2015-06, Vol.36 (6), p.4655</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids></links><search><creatorcontrib>Cieliska, Anna</creatorcontrib><creatorcontrib>Sienkiewicz-szapka, Edyta</creatorcontrib><creatorcontrib>Kostyra, Elbieta</creatorcontrib><creatorcontrib>Fiedorowicz, Ewa</creatorcontrib><creatorcontrib>Snarska, Jadwiga</creatorcontrib><creatorcontrib>Wroski, Konrad</creatorcontrib><creatorcontrib>Tenderenda, Micha</creatorcontrib><creatorcontrib>Jarmoowska, Beata</creatorcontrib><creatorcontrib>Matysiewicz, Micha</creatorcontrib><title>[mu]-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer</title><title>Tumor biology</title><description>Structure-dependent [mu]-opioid receptor (MOR) activity is an important element in cancer opioid analgesic effectiveness. It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern. This is associated with decreased binding ability in both exogenous and endogenous opioids, resulting in increased human pain resistance. The endogenous opioid system's function in body homeostasis maintenance is considered mainly regulatory, so its participation in breast tumor formation and progression is identified herein. We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies. Our results highlight a strong association between G allele presence at [mu]-opioid receptor A118G and increased breast cancer incidence (OR=3.3, 95 % CI 2.2-5.0, p<0.0001) and female gender (OR=2.0, 95 % CI 1.4-2.9, p=0.0004). Consequently, OPRM1 G allele presence at that site is a highly significant risk factor in breast cancer development.</description><subject>Analgesics</subject><subject>Breast cancer</subject><subject>Homeostasis</subject><subject>Pain management</subject><subject>Polymorphism</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNisFOAjEUABsDiSB8gLeXeMFD9b12tXA2Gi5kCeFmCFmWp5SwbW27Ifr17oEP4DSTzAhxT_hEiOY5kVbGSKQXqYm0_LsRAyqUlqin2OscCWWhpvpWDFM6YjfOZq8Dsfhs2o0sg_V2D5FrDtlH-GbHMCmXqwU9QvCn38bHcLCpAesgVNmyywnONh9gF7lKGerK1RxHov9VnRKPL7wTDx_v67e5DNH_tJzy9ujb6Lq0JYNKEZrC6Ouuf-26Q-Q</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Cieliska, Anna</creator><creator>Sienkiewicz-szapka, Edyta</creator><creator>Kostyra, Elbieta</creator><creator>Fiedorowicz, Ewa</creator><creator>Snarska, Jadwiga</creator><creator>Wroski, Konrad</creator><creator>Tenderenda, Micha</creator><creator>Jarmoowska, Beata</creator><creator>Matysiewicz, Micha</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20150601</creationdate><title>[mu]-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer</title><author>Cieliska, Anna ; Sienkiewicz-szapka, Edyta ; Kostyra, Elbieta ; Fiedorowicz, Ewa ; Snarska, Jadwiga ; Wroski, Konrad ; Tenderenda, Micha ; Jarmoowska, Beata ; Matysiewicz, Micha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_17022107473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analgesics</topic><topic>Breast cancer</topic><topic>Homeostasis</topic><topic>Pain management</topic><topic>Polymorphism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cieliska, Anna</creatorcontrib><creatorcontrib>Sienkiewicz-szapka, Edyta</creatorcontrib><creatorcontrib>Kostyra, Elbieta</creatorcontrib><creatorcontrib>Fiedorowicz, Ewa</creatorcontrib><creatorcontrib>Snarska, Jadwiga</creatorcontrib><creatorcontrib>Wroski, Konrad</creatorcontrib><creatorcontrib>Tenderenda, Micha</creatorcontrib><creatorcontrib>Jarmoowska, Beata</creatorcontrib><creatorcontrib>Matysiewicz, Micha</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cieliska, Anna</au><au>Sienkiewicz-szapka, Edyta</au><au>Kostyra, Elbieta</au><au>Fiedorowicz, Ewa</au><au>Snarska, Jadwiga</au><au>Wroski, Konrad</au><au>Tenderenda, Micha</au><au>Jarmoowska, Beata</au><au>Matysiewicz, Micha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[mu]-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer</atitle><jtitle>Tumor biology</jtitle><date>2015-06-01</date><risdate>2015</risdate><volume>36</volume><issue>6</issue><spage>4655</spage><pages>4655-</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Structure-dependent [mu]-opioid receptor (MOR) activity is an important element in cancer opioid analgesic effectiveness. It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern. This is associated with decreased binding ability in both exogenous and endogenous opioids, resulting in increased human pain resistance. The endogenous opioid system's function in body homeostasis maintenance is considered mainly regulatory, so its participation in breast tumor formation and progression is identified herein. We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies. Our results highlight a strong association between G allele presence at [mu]-opioid receptor A118G and increased breast cancer incidence (OR=3.3, 95 % CI 2.2-5.0, p<0.0001) and female gender (OR=2.0, 95 % CI 1.4-2.9, p=0.0004). Consequently, OPRM1 G allele presence at that site is a highly significant risk factor in breast cancer development.</abstract><cop>London</cop><pub>Springer Nature B.V</pub><doi>10.1007/s13277-015-3113-z</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2015-06, Vol.36 (6), p.4655 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_journals_1702210747 |
| source | SpringerLink Journals |
| subjects | Analgesics Breast cancer Homeostasis Pain management Polymorphism |
| title | [mu]-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T20%3A37%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5Bmu%5D-Opioid%20receptor%20gene%20(OPRM1)%20polymorphism%20in%20patients%20with%20breast%20cancer&rft.jtitle=Tumor%20biology&rft.au=Cieliska,%20Anna&rft.date=2015-06-01&rft.volume=36&rft.issue=6&rft.spage=4655&rft.pages=4655-&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-015-3113-z&rft_dat=%3Cproquest%3E3771765211%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1702210747&rft_id=info:pmid/&rfr_iscdi=true |